[The dynamics of the immunological indices during the treatment of recurrent erysipelas with the new immunostimulant bemitil].
Bemitil, administered orally in a dose of 0.25-0.5 g a day for 5-7 days at the acute period of the relapse of erysipelas as an immunostimulant, enhanced the effectiveness of the basic therapy including antibiotics, anti-inflammatory and antiallergic drugs, vitamins, plasma-substituting fluids and saline solutions, as well as ultraviolet irradiation of the focus of lesion. Bemitil therapy was associated with an increase in the number of T-lymphocytes, normalization of the balance between the peripheral lymphocyte preparations, an increase of blood serum levels of IgA and IgM.
Ratnikova
L I
LI
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D001562:Benzimidazoles / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004886:Erysipelas / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007902:Length of Stay; D012008:Recurrence; D013997:Time Factors
D000276:Adjuvants, Immunologic; D001562:Benzimidazoles; C049825:bemethyl
Dinamika nekotorykh immunologicheskikh pokazateleĭ pri lechenii retsidiviruiushcheĭ rozhi novym immunostimuliatorom bemitilom.